Use of soybean meal-based moxifloxacin pellets in equine nutrition and health
Abstract
Pellets formulated from organic biomass, such as soybean meal, are increasingly used in animal nutrition and controlled drug delivery systems. This review aims to explore the advancements and challenges in developing and evaluating soybean meal-based moxifloxacin pellets specifically for equine applications. The focus includes production techniques, the role of soybean meal in equine diets, and the therapeutic potential of moxifloxacin. Soybean meal, known for its high protein and lysine content, is a valuable feed component for equines and offers advantages in pellet formulation. Moxifloxacin, a broad-spectrum antibiotic, has shown effectiveness in treating a range of bacterial infections in horses, with the added benefit of controlled release when delivered in pellet form. This combination presents a novel strategy for improving both nutrition and targeted medication in equines. However, further research is required to assess its safety and therapeutic efficacy.
How strong is the evidence?
Evidence Hub reads this as a review, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.